Active surveillance for low-risk prostate cancer

Selection of patients and predictors of progression

Marc Dall'Era, Badrinath R. Konety

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The natural history of prostate cancer is often of long duration, and the disease is incompletely understood. Whether all men with prostate cancer require immediate treatment or whether men with tumors of low malignant potential are being overtreated with potentially harmful therapies is a subject of much debate. Results from a randomized trial that compared watchful waiting and active therapy showed all-cause and disease-specific survival advantages with radical therapy, but the study group was mixed in terms of disease risk; the optimum treatment strategy for men with low risk features remains unclear. Multiple centers are gaining experience with active surveillance and delayed intervention with curative intent for men with prostate tumors of potentially low clinical risk. This Review describes the background studies behind the rationale for active surveillance, thoughts on selection criteria for candidates and some early reported outcomes for active surveillance cohorts. The psychosocial impact of active surveillance on patients is discussed as well as contemporary methods for disease monitoring.

Original languageEnglish (US)
Pages (from-to)277-283
Number of pages7
JournalNature Clinical Practice Urology
Volume5
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

Patient Selection
Prostatic Neoplasms
Watchful Waiting
Therapeutics
Group Psychotherapy
Prostate
Neoplasms
Survival

ASJC Scopus subject areas

  • Urology
  • Nephrology

Cite this

Active surveillance for low-risk prostate cancer : Selection of patients and predictors of progression. / Dall'Era, Marc; Konety, Badrinath R.

In: Nature Clinical Practice Urology, Vol. 5, No. 5, 05.2008, p. 277-283.

Research output: Contribution to journalArticle

@article{f60b6643c47c4d93b09881e2ab5239c6,
title = "Active surveillance for low-risk prostate cancer: Selection of patients and predictors of progression",
abstract = "The natural history of prostate cancer is often of long duration, and the disease is incompletely understood. Whether all men with prostate cancer require immediate treatment or whether men with tumors of low malignant potential are being overtreated with potentially harmful therapies is a subject of much debate. Results from a randomized trial that compared watchful waiting and active therapy showed all-cause and disease-specific survival advantages with radical therapy, but the study group was mixed in terms of disease risk; the optimum treatment strategy for men with low risk features remains unclear. Multiple centers are gaining experience with active surveillance and delayed intervention with curative intent for men with prostate tumors of potentially low clinical risk. This Review describes the background studies behind the rationale for active surveillance, thoughts on selection criteria for candidates and some early reported outcomes for active surveillance cohorts. The psychosocial impact of active surveillance on patients is discussed as well as contemporary methods for disease monitoring.",
author = "Marc Dall'Era and Konety, {Badrinath R.}",
year = "2008",
month = "5",
doi = "10.1038/ncpuro1058",
language = "English (US)",
volume = "5",
pages = "277--283",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Active surveillance for low-risk prostate cancer

T2 - Selection of patients and predictors of progression

AU - Dall'Era, Marc

AU - Konety, Badrinath R.

PY - 2008/5

Y1 - 2008/5

N2 - The natural history of prostate cancer is often of long duration, and the disease is incompletely understood. Whether all men with prostate cancer require immediate treatment or whether men with tumors of low malignant potential are being overtreated with potentially harmful therapies is a subject of much debate. Results from a randomized trial that compared watchful waiting and active therapy showed all-cause and disease-specific survival advantages with radical therapy, but the study group was mixed in terms of disease risk; the optimum treatment strategy for men with low risk features remains unclear. Multiple centers are gaining experience with active surveillance and delayed intervention with curative intent for men with prostate tumors of potentially low clinical risk. This Review describes the background studies behind the rationale for active surveillance, thoughts on selection criteria for candidates and some early reported outcomes for active surveillance cohorts. The psychosocial impact of active surveillance on patients is discussed as well as contemporary methods for disease monitoring.

AB - The natural history of prostate cancer is often of long duration, and the disease is incompletely understood. Whether all men with prostate cancer require immediate treatment or whether men with tumors of low malignant potential are being overtreated with potentially harmful therapies is a subject of much debate. Results from a randomized trial that compared watchful waiting and active therapy showed all-cause and disease-specific survival advantages with radical therapy, but the study group was mixed in terms of disease risk; the optimum treatment strategy for men with low risk features remains unclear. Multiple centers are gaining experience with active surveillance and delayed intervention with curative intent for men with prostate tumors of potentially low clinical risk. This Review describes the background studies behind the rationale for active surveillance, thoughts on selection criteria for candidates and some early reported outcomes for active surveillance cohorts. The psychosocial impact of active surveillance on patients is discussed as well as contemporary methods for disease monitoring.

UR - http://www.scopus.com/inward/record.url?scp=43449110157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449110157&partnerID=8YFLogxK

U2 - 10.1038/ncpuro1058

DO - 10.1038/ncpuro1058

M3 - Article

VL - 5

SP - 277

EP - 283

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 5

ER -